Drug Approval | June 14, 2022
FDA accepts application for Merck’s Keytruda as adjuvant therapy for Stage IB-IIIA lung cancer
Acceptance based on results from the phase 3 KEYNOTE-091 trial
Acceptance based on results from the phase 3 KEYNOTE-091 trial
Next-generation booster vaccine candidate demonstrates potential to protect against COVID-19 variants of concern, including Omicron BA.1 and BA.2, with a favorable safety and tolerability profile
Strides was granted a Competitive Generic Therapy (CGT) designation for its ANDA.
India’s first oncology laboratory for comprehensive Cancer Diagnostic services
Doubling of median overall survival seen in QuANTUM-First results presented at EHA Presidential Symposium
Dasatinib Tablet is indicated for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive
The production and supply in Canada are designed to address the growing need for no-carrier-added Lutetium-177 (n.c.a. Lu-177) in North America
Tislelizumab is now approved in nine indications in China
Centre of Excellence at Kharel comprises Skill-building Centre and Primary, Secondary and Higher Secondary schools
Plans to establish six state of the art TaCa Centre for Surgery in next 2 years in these states
Subscribe To Our Newsletter & Stay Updated
